Following a cancer diagnosis, dietary supplements are reportedly used by 20%–80% of individuals. Supplements are most commonly used by breast cancer survivors, followed by patients with prostate, colorectal, and lung cancers, which is not surprising since these are the most common types of cancer diagnosed in adults. Reasons cited for such use include improving quality of life, reducing symptoms related to treatment and/or the disease process, and recommendation from medical practitioners; family and friends may also be an influence. However, controversy surrounds the use of dietary supplements, particularly during treatment—specifically, whether supplements affect treatment efficacy is unknown. This article discusses the evidence related to common dietary supplements used to prevent cancer or a recurrence.
BaileyRLGahcheJJLentinoJJ. Dietary supplement use in the United States, 2003-2006. J Nutr. 2001;14(192):261-266.
2.
ZirpoliGRBrennanPMHongCCSupplement use during an intergroup clinical trial for breast cancer (S0221). Breast Cancer Res Treat. 2013;137:903-913.
3.
KantorEDRehmCDDuMWhiteEGiovannucciEL. Trends in dietary supplement use among US adults from 1999-2012. JAMA. 2016;316(14):1464-1474.
4.
JatoiAWilliamsBNicholsFIs voluntary vitamin and mineral supplementation associated with better outcome in non–small cell lung cancer patients? Results from the Mayo Clinic lung cancer cohort. Lung Cancer. 2005;49(1):77-84.
5.
FerrucciLMMcCorkelRSmithTSteinKDCartmelB. Factors related to the use of dietary supplements by cancer survivors. J Altern Complement Med. 2009;15(6):673-680.
6.
LuoQAsherGN. Complementary and alternative medicine use at a comprehensive cancer center [published online May 4, 2016]. Integr Cancer Ther.
7.
ReedyJHainesPSStecklerACampbellMK. Qualitative comparison of dietary choices and dietary supplement use among older adults with and without a history of colorectal cancer. J Nutr Educ Behav. 2005;37:252-258.
8.
Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study Group. The effect of vitamin E and beta-carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med. 1994;330(15):1029-1035.
9.
OmennGSGoodmanGEThornquistMDRisk factors for lung cancer and for intervention effects in CARET, the Beta-Carotene and Retinol Efficacy Trial. J Natl Cancer Inst. 1996;88(21):1550-1559.
10.
GazianoJMSessoHDChristenWGMultivitamin in the prevention of cancer in men: the Physicians Health Study II randomized controlled trial. JAMA. 2012;308(18):1871-1880.
11.
DunnBKRichmondESMinasianLMRyanAMFordLG. A nutrient approach to prostate cancer prevention: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Nutr Cancer. 2010;62(7):896-918.
12.
SatiaJALittmanASlatoreCGGalankoJAWhiteE. Long-term use of β-carotene, retinol, lycopene, and lutein supplements and lung cancer risk: results from the Vitamins and Lifestyle (VITAL) study. Am J Epidemiol. 2009;169(7):815-828.
13.
HanXLiJBraskyTMAntioxidant intake and pancreatic cancer risk: the Vitamins and Lifestyle (VITAL) study. Cancer. 2013;119(7):1314-1320.
14.
DawseySPHollenbeckASchatzkinAAbnetCC. A prospective study of vitamin and mineral supplement use and the risk of upper gastrointestinal cancers. PLoS One. 2014;9(2):e88774.
15.
NeuhouserMLWassertheil-SmollerSThomsonCAMultivitamin use and risk of cancer and cardiovascular disease in the Women’s Health Initiative Cohorts. Arch Intern Med. 2009;169(3):294-304.
16.
SaquibJRockCLNatarajanLDietary intake, supplement use, and survival among women diagnosed with early-stage breast cancer. Nutr Cancer. 2011;63:327-333.
17.
JacobsEJConnellCJPatelAVMultivitamin use and colon cancer mortality in the Cancer Prevention Study II cohort (United States). Cancer Causes Control. 2001;12(10):927-934.
18.
GiovannucciEStampferMColditzGA. Multivitamin use, folate and colon cancer in women in the Nurses’ Health Study. Ann Intern Med. 1998;129(7):517- 524.
19.
KwanMLGreenleeHLeeVSMultivitamin use and breast cancer outcomes in women with early-stage breast cancer: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. 2011;130(1):195-205.
20.
NechutaSLuWChenZVitamin supplement use during breast cancer treatment and survival: a prospective cohort study. Cancer Epidemiol Biomark Prev. 2011;20:262-271.
21.
Wassertheil-SmollerSMcGinnAPBudrysNMultivitamin and mineral use and breast cancer mortality in older women with invasive breast cancer in the women’s health initiative. Breast Cancer Res Treat. 2013;141(3):495-505.
22.
NgKVenookAPSatoKVitamin D status and survival of metastatic colorectal cancer patients: results from CALCG/SWOG 80405 (Alliance) [abstract 507]. J Clin Oncol. 2015;33(suppl 3).
23.
Inoue-ChoiMGreenleeHOppeneerSJRobienK. The association between postdiagnosis dietary supplement use and total mortality differs by diet quality among older female cancer survivors. Cancer Epidemiol Biomarkers. 2014;23(5):865-875.
KwanMLWeltzienEKushiLHCastilloASlatteryMLCaanBJ. Dietary patterns and breast cancer recurrence and survival among women with early stage breast cancer. Clin Oncol. 2009;27(6):919-926.
27.
KrishnanAVFeldmanD. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Ann Rev Pharmacol Toxicol. 2011;10(51):311-336.
28.
PilzSTomaschitzAObermayer-PietschBDobnigHPieberTF. Epidemiology of vitamin D insufficiency and cancer mortality. Anticancer Res. 2009;29(9):3699-3704.
29.
JacobsETKohlerLNKunihiroAGJurutkaPW. Vitamin D and colorectal, breast, and prostate cancers: a review of the epidemiological evidence. J Cancer. 2016;7(3):232-240.
30.
ChoMPeddiPFDingKVitamin D deficiency and prognostics among patients with pancreatic adenocarcinoma. J Transl Med. 2013:11:206.
31.
DarlingALAbarLNoratT. WCRF-AICR continuous update project: systematic literature of prospective studies on circulating 25-hydroxyvitamin D and kidney cancer risk. J Steroid Biochem Mol Biol. 2016;164:85-89.
32.
OngJSCuellar-PartidaGLuYAssociation of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. Int J Epidemiol. 2016;45(5):1619-1630.
33.
ZgagaLTheodoratouEFarringtonSMPlasma vitamin D concentration influences survival out-come after a diagnosis of colorectal cancer. J Clin Oncol. 2014;32(23):2430-2439.
34.
GiovannucciELiuYRimmEBProspective study of predictors of vitamin D status and cancer incidence and mortality in men. J Natl Cancer Inst. 2006;98(7):451-459.
35.
TouvierMChanDSLlauRMeta-analyses of vitamin D intake, 25-hydroxyvitamin D status, vitamin D receptor polymorphisms, and colorectal cancer risk. Cancer Epidemiol Biomarkers Prev. 2011;20:1003-1016.
36.
TrowbridgeRMittalSKAgrawalDK. Vitamin D and the epidemiology of upper gastrointestinal cancers: a critical analysis of the current evidence. Cancer Epidemiol Biomarkers Prev. 2013;22(6):1007-1014.
37.
LappeJMTravers-GustafsonDDaviesKMReckerRRHeaneyRP. Vitamin D and calcium supplementation reduces cancer risk: results of a randomized trial. Am J Clin Nutr. 2007;85(6):1586-1591.
38.
LappeJMWatsonPTravers-GustafsonDEffect of vitamin D and calcium supplementation on cancer incidence in older women: a randomized clinical trial. JAMA. 2017;317(12):1234-1243.
39.
BollandMJGreyAGambleGDReidIR. Calcium and vitamin D supplements and health outcomes: a reanalysis of the Women’s Health Initiative (WHI) limited-access data set. Am J Clin Nutr. 2011;94(4):1144-1149.
40.
ZhouWHeistRSLiuGVitamin D is associated with improved survival in early-stage non–small cell lung cancer patients. Cancer Epidemiol Biomarkers Prev. 2005;14(10):2303-2309.
41.
ZhouWHeistRSLiuGCirculating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients. J Clin Oncol. 2007;25(5):479-485.
42.
ChenGCZhangZLWanZCirculating 25-hydroxyvitamin D and risk of lung cancer: a dose-response meta-analysis. Cancer Causes Control. 2015;26:1719-1728.
43.
ZhangLWangSCheXLiX. Vitamin D and lung cancer risk: a comprehensive review and meta-analysis. Cell Physiol Biochem. 2015;36:299-305.
44.
TretilSSchwartzGGTorjesenPARobsahmTE. Serum levels of 15-hydroxyvitamin D and survival in Norwegian patients with cancer of breast, colon, lung, and lymphoma: a population-based study. Cancer Causes Control. 2012;23(2):363-370.
45.
WeinsteinSJYuKHorstRLParisiDVirtamoJAlbanesD. Serum 25-hydroxyvitamin d and risk of lung cancer in male smokers: a nested case-control study. PLoS One. 2011;6:e20796.
46.
HeistRSZhouWWangZCirculating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer. J Clin Oncol. 2008;26(34):5596-5602.
47.
WuXChengJYangK. Vitamin D–related gene polymorphisms, plasma 25-hydroxy-vitamin D, cigarette smoke and non–small cell lung cancer (NSCLC) risk. In J Mol Sci. 2016;17(10):E1597.
48.
ChengTYLaCroixAZBeresfordSAAVitamin D intake and lung cancer risk in the Women’s Health Initiative. Am J Clin Nutr. 2013;98(4):1002-1011.
49.
MaYZhangPWangFYangJLiuZQinH. Association between vitamin D and risk of colorectal cancer: a systematic review of prospective studies. J Clin Oncol. 2011;29(28):3775-3782.
50.
MohrSBGorhamEDKimJHofflichHCuomoREGarlandCF. Could vitamin D sufficiency improve the survival of colorectal cancer patients?J Steroid Biochem Mol Biol. 2015;148:239-244.
51.
FacciorussoADel PreteVMuscatielloNCrucinioNBaroneM. Prognostic role of 25-hydroxyvitamin D in patients with liver metastases from colorectal cancer treated with radiofrequency ablation. J Gastroenterol Hepatol. 2016;31(8):1483-1488.
52.
Wactawski-WendeJKotchenJMAndersonGLCalcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med. 2006;354:684-696.
53.
TrivediDPDollRKhawKT. Effect of four monthly oral vitamin D3 (cholecalciferol) supplementation on fractures and morality in men and women living in the community: randomized double blind controlled trial. BMJ. 2003;326(7387):469.
54.
ChenPLiMGuXHigher blood 25(OH)D level may reduce the breast cancer risk: evidence from a Chinese population based case-control study and meta-analysis of the observational studies. PloS One. 2013;8:e49312
55.
JacobsETThomsonCAFlattSWVitamin D and breast cancer recurrence in the Women’s Healthy Eating and Living (WHEL) study. Am J Clin Nutr. 2011;93:108-117.
56.
ButtiglieroCMonaghedduCPetroniPPrognostic role of vitamin d status and efficacy of vitamin D supplementation in cancer patients: a systematic review. Oncologist. 2011;16(9):1215-1227.
57.
EliassenAHWarnerETRosnerBPlasma 25-hydroxyvitamin D and risk of breast cancer in women followed over 20 years. Cancer Res. 2016;76(18):5423-5430.
58.
McDonnellSLBaggerlyCFrenchCBSerum 25-hydroxyvitamin D concentrations ≥40 ng/mL are associated with >65% lower cancer risk: pooled analysis of randomized trial and prospective cohort study. PLoS One. 2016;11(4):e0152441.
59.
YaoSKwanMLErgasIJAssociation of serum levels of vitamin D at diagnosis with breast cancer survival: a case-cohort analysis in the Pathways Study. JAMA Oncol. 2017;3(3):351-357.
60.
MohrSBGorhamEDKimJHofflichHGarlandCF. Meta-analysis of vitamin D sufficiency for improving survival of patients with breast cancer. Anticancer Res. 2014;34(3):1163-1166.
61.
KimYJeY. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality: a meta-analysis. Br J Cancer. 2014;110:2772-2778.
62.
VrielingASeiboldPJohnsonTSCirculating 25-hydroxyvitamin D and postmenopausal breast cancer survival: influence of tumor characteristics and lifestyle factors?Int J Cancer. 2014;134:2972-2983.
63.
ChlebowskiRTJohnsonKCKooperbergCCalcium plus vitamin D supplementation and the risk of breast cancer. J Natl Cancer Inst. 2008;100:1581-1591.
64.
ZeichnerSBKoru-SengulTShahNImproved clinical outcomes associated with vitamin D supplementation during adjuvant chemotherapy in patients with HER2+ nonmetastatic breast cancer. Clinical Breast Cancer. 2015;15(1):e1-e11.
65.
AhonenMHTenkanenLTeppoLProstate cancer risk and prediagnostic serum 25-hydroxyvitamin D levels (Finland). Cancer Causes Control. 2000;11:847-852.
66.
GilbertRMetcalfeCFraserWKAssociation of circulating 25-hydroxyvitamin D with prostate cancer diagnosis, stage and grade. Int J Cancer. 2012;131:1187-1196.
67.
ShuiIMMucciLAKraftPVitamin D–related genetic variation, plasma vitamin D, and risk of lethal prostate cancer: a prospective nested case-control study. J Natl Cancer Inst. 2012;104:690-699.
68.
KristalARTillCSongXPlasma vitamin D and prostate cancer risk: results from the Selenium and Vitamin E Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014;23:1494-1504.
69.
SchenkJMTillCATangenCMSerum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer Epidemiol Biomarkers Prev. 2014;23:1484-1493.
70.
XuYShaoXYaoYPositive association between circulating 25-hydroxyvitamin D levels and prostate cancer risk: new findings from an updated meta-analysis. J Cancer Res Clin Oncol. 2014;140:1465-1477.
71.
MarshallDTSavageSJGarrett-MayerEVitamin D3 supplementation at 4000 international units per day for one year results in a decrease of positive cores at repeat biopsy in subjects with low-risk prostate cancer under active surveillance. J Clin Endocrinol Metab. 2012;97:2315-2324.
72.
FangFKasperzykJLShuiIPrediagnostic plasma vitamin D metabolites and mortality among patients with prostate cancer. PloS One. 2011;6e18625.
73.
TretliSHernesFBergJPAssociation between serum 25(OH)D and death from prostate cancer. Br J Cancer. 2009;100:450-454.
74.
Nesby-O’DellSScanlonKSCogswellMEHypovitaminosis D prevalence and determinants among African American and white women of reproductive age: Third National Health and Nutrition Examination Survey, 1988-1994. Am J Clin Nutr. 2002;76:187-192.
75.
HanleyDADavisonKS. Vitamin D insufficiency in North America. J Nutr. 2005;135:332-337.
76.
WaterhouseMRischHABosettiCVitamin D and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Case-Control Consortium. Ann Oncol. 2015;26(8):1776-1783.
77.
Stolzenberg-SolomonRZ. Vitamin D and pancreatic cancer. Ann Epidemiol. 2009;19(2):89-95.
78.
McGovernEMLewisMENiesleyMLHuynhNHoagJB. Retropsective analysis of the influence of 15-hydroxyvitamin D on disease progression and survival in pancreatic cancer. Nutr J. 2016;12:15-17.
79.
NgACKumarSKRajkumarSVDrakeMT. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am J Hematol. 2009;84:397-400.
80.
SfeirJGDrakeMTLaPlantBRValidation of a vitamin D replacement strategy in vitamin D–insufficient patients with lymphoma or chronic lymphocytic leukemia. Blood Cancer J. 2017;7(2):e526.
81.
ThotaPNKistangariGSinghPSerum 25-hydroxyvitamin D levels and the risk of dysplasia and esophageal adenocarcinoma in patients with Barrett’s esophagus. Dig Dis Sci. 2016;61(1):247-254.
82.
WangLWangCWangJLongitudinal, observational study on associations between postoperative nutritional vitamin D supplementation and clinical outcomes in esophageal cancer patients undergoing esophagectomy. Sci Rep. 2016;6:38962.
83.
MullerDCFanidiAMidttunØCirculating 25-hydroxyvitamin D3 in relation to renal cell carcinoma incidence and survival in the EPIC cohort. Am J Epidemiol. 2014;180(8):810-820.
84.
ZhangHZhangHWenXZhangYWeiXLiuT. Vitamin D deficiency and increased risk of bladder carcinoma: a meta-analysis. Cell Physiol Biochem. 2015;37(5):1686-1692.
85.
KhayatzadehSFeiziASaneeiPEsmaillzadehA. Vitamin D intake, serum vitamin D levels, and risk of gastric cancer: a systematic review and meta-analysis. J Res Med Sci. 2015;20(8):790-796.
86.
YinLGrandiNRaumEHaugUArndtVBrennerH. Meta-analysis: circulating vitamin D and ovarian cancer risk. Gynecol Oncol. 2011;121(2):369-375.
87.
CookLSNeilsonHKLorenzettiDLLeeRC. A systematic literature review of vitamin D and ovarian cancer. Am J Obstet Gynecol. 2010;203:70.e1-e8.
88.
MoukayedMGrantWB. The roles of UVB and vitamin D in reducing risk of cancer incidence and mortality: a review of the epidemiology, clinical trials, and mechanisms [published online February 17, 2017]. Rev Endocr Metab Disord.
89.
KennelKADrakeMT. Vitamin D in the cancer patient. Curr Opin Support Palliat Care. 2013;7(3):272-277.
90.
ByersTEGrahamSHaugheyBPMarshallJRSwansonMK. Diet and lung cancer risk: findings from the Western New York Diet Study. Am J Epidemiol. 1987;125(3):351-363.
91.
ZieglerRGMasonTJStemhagenADietary carotene and vitamin A and risk of lung cancer among white men in New Jersey. J Natl Cancer Inst. 1984;73(6):1429-1435.
92.
VirtamoJPietinenPHuttanenJKIncidence of cancer and mortality following alpha-tocopherol and beta-carotene supplementation: a posttrial follow-up. JAMA. 2003;290(4):476-485.
93.
LeeIMCookNRMansonJEBuringJEHennekensCH. Beta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women’s Health Study. J Natl Cancer Inst. 1999;91(24):2102-2106.
94.
CookNRLeIMMansonJEBuringJEHennekensCH. Effects of beta-carotene supplementation on cancer incidence by baseline characteristic in the Physicians’ Health Study (United States). Cancer Causes Control. 2000;11(7):617-626.
95.
GallicchioLBoudKMatanoskiGCarotenoids and the risk of developing lung cancer: a systematic review. Am J Clin Nutr. 2008;88:372-383.
96.
KimJKimY. Animal models in carotenoids research and lung cancer prevention. Transl Oncol. 2011;4(5):271-281.
97.
Mut-SaludNAlvarezPGarridoJMCarrascoEArangeaARodriguez-SerranoF. Antioxidant intake and antitumor therapy: toward nutritional recommendations for optimal results. Oxid Med Cell Longev. 2016;2016:6719534.
98.
BlockKIKochACMeadMNImpact of antioxidant supplementation on chemotherapeutic efficacy: a systematic review of the evidence fro randomized controlled trials. Cancer Treat Rev. 2007;33:407-418.
99.
YasendaAUrushimaHItoT. Efficacy and interaction of antioxidant supplements as adjuvant therapy in cancer treatment: a systematic review. Integr Cancer Ther. 2016;15(1):17-39.
100.
ChandelNSTuvesonDA. The promise and perils of antioxidants for cancer patients. N Engl J Med. 2014;371:177-178.
101.
GorriniCHarrisISMakTW. Modulation of oxidative stress as an anticancer strategy. Nat Rev Drug Discov. 2013;12:931-947.
102.
BlotWJLiJYTaylorPRNutrition intervention trials in Linxian, China: supplementation with specific vitamin/mineral combinations, cancer incidence, and disease-specific mortality in the general population. J Natl Cancer Inst. 1993;85:1483-1491.
103.
QiaoYLDawseySMKamangarFTotal and cancer mortality after supplementation with vitamins and minerals: follow-up of the Linxian general population nutrition intervention trial. J Natl Cancer Inst. 2009;101(7):507-518.
104.
LeeIMCookNRMansonJEBeta-carotene supplementation and incidence of cancer and cardiovascular disease: the Women’s Health Study. J Natl Cancer Inst. 1999;91(24):2102-2106.
105.
LeeIMCookNRGazianoJMVitamin E in the primary prevention of cardiovascular disease and cancer: the Women’s Health Study. A randomized controlled trial. JAMA. 2005;29(1):56-65.
106.
LinJCookNRAlbertCVitamins C and E and beta carotene and cancer risk: a randomized controlled trial. J Natl Cancer Inst. 2009;101(1):14-23.
107.
MeyerFGalanPDouvillePAntioxidant vitamin and mineral supplementation and prostate cancer prevention in the SU.VI.MAX trial. Int J Cancer. 2005;116(2):182-186.
108.
BairatiIMeyerFGelinasMRandomized trial of antioxidant vitamins to prevent acute adverse effects of radiation therapy in head and neck cancer patients. J Clin Oncol. 2005;23(24):5805-5813.
109.
MeyerFBairatiIFortinAInteraction between antioxidant vitamin supplementation and cigarette smoking during radiation therapy in relation to long-term effects on recurrence and mortality: a randomized trial among head and neck cancer patients. Int J Cancer. 2008;122(7):1679-1683.
110.
FerreiraPRFleckJFDiehlAProtective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck. 2004;26(4):313-321.
111.
LesperanceMLOlivottoIAFordeNMega-dose vitamins and minerals in the treatment of non-metastatic breast cancer: an historical cohort study. Breast Cancer Res Treat. 2002;76(2):137-143.
112.
PathakAKBhutaniMGuleriaRChemotherapy alone vs chemotherapy plus high dose multiple antioxidants in patients with advanced non small cell lung cancer. J Am Coll Nutr. 2005;24(1):16-21.
113.
SchneiderC. Chemistry and biology of vitamin E. Mol Nutr Food Res. 2005;49:7-30.
114.
RoswallNOlsenAChristensenJDragstedLOOvervadKTjønnelandA. Source-specific effects of micronutrients in lung cancer prevention. Lung Cancer. 2010;67:275-281.
115.
AntwiSSteckSESuLJDietary, supplement, and adipose tissue tocopherols levels in relation to prostate cancer aggressiveness among African and European Americans: the North Carolina–Louisiana Prostate Cancer Project (PCaP). Prostate. 2015;75(13):1419-1435.
116.
KleinEAThompsonIMJrTangenCMVitamin E and the risk of prostate cancer: the Selenium and Vitamin E Cancer Prevention Trial (SELECT). JAMA. 2011;306(14):1549-1556.
117.
WangLSessoHDGlynnRJVitamin E and C supplementation and risk of cancer in men: posttrial follow-up in the Physicians’ Health Study II randomized trial. Am J Clin Nutr. 2014;100:915-923.
118.
AlbanesDTillCKleinEAPlasma tocopherols and risk of prostate cancer in the Selenium and Vitamin E Cancer Prevention Trial (SELECT). Cancer Prev Res (Phila). 2014;7(9):886-895.
119.
WadleighRGRedmanRSGrahamMLKrasnowSHAndersonACohenMH. Vitamin E in the treatment of chemotherapy-induced mucositis. Am J Med. 1992;92:481-484.
120.
PaceASavareseAPicardoMNeuroprotective effect of vitamin E supplementation in patients treated with cisplatin chemotherapy. J Clin Oncol. 2003;21:927-931.
121.
KottschadeLASloanJAMazurczakMAThe use of vitamin E for the prevention of chemotherapy-induced peripheral neuropathy: results of a randomized phase III clinical trial. Support Care Cancer. 2011;19:1769-1777.
122.
ArgyriouAAChroniEKoutrasAA randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer. 2006;14:1134-1140.
123.
PaceAGiannarelliDGalieEVitamin E neuroprotection for cisplatin neuropathy: a randomized, placebo controlled trial. Neurology. 2010;74:762-766.
124.
HeaneyMGardnerJKarasavvasNVitamin C antagonizes the cytotoxic effects of antineoplastic drugs. Cancer Res. 2008;68(19):8031-8038.
125.
ChenQEspeyMGSunAYPharmacologic doses of ascorbate act as a prooxidant and decrease growth of aggressive tumor xenografts in mice. Proc Natl Acad Sci U S A. 2008;105(32):11105-11109.
126.
CameronEPaulingL. Supplemental ascorbate in the supportive treatment of cancer: prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1976;73(10):3685-3689.
127.
CameronEPaulingL. Supplemental ascorbate in the supportive treatment of cancer: reevaluation of prolongation of survival times in terminal human cancer. Proc Natl Acad Sci U S A. 1978;75(9):4538-4542.
128.
HosokawaYSagaRMonzenSTerashimaSTsurugaE. Ascorbic acid does not reduce the anticancer effect of radiotherapy. Biomed Rep. 2017;6(1):103-107.
129.
CreaganEMortalCO’FallonJFailure of high-dose vitamin C (ascorbic acid) therapy to benefit patients with advanced cancer: a controlled trial. N Engl J Med. 1979;301(13):687-690.
130.
MoertlCFlemingTCreaganEHigh-dose vitamin C versus placebo in the treatment of patient with advanced cancer who have had no prior chemotherapy: a randomized double-blind comparison. N Engl J Med. 1985;312(3):137-141.
131.
MaYChapmanJLevineMHigh-dose parenteral ascorbate enhanced chemosensitivity of ovarian cancer and reduced toxicity of chemotherapy. Sci Transl Med. 2014;6(222):222ra18.
132.
MontiDMitchellEBazzanAPhase I evaluation of intravenous ascorbic acid in combination with gemcitabine and erlotinib in patients with metastatic pancreatic cancer. PLoS One. 2012;7(1):e29794.
133.
WelshJWagnerBvan’t ErveTPharmacological ascorbate with gemcitabine for the control of metastatic and node-positive pancreatic cancer (PACMAN): results from a phase I clinical trial. Cancer Chemother Pharmacol. 2013;71(3):765-775.
134.
HerstPBroadleyKHarperJMcConnellM. Pharmacological concentrations of ascorbate radiosensitize glioblastoma multiform primary cells by increasing oxidative DNA damage and inhibiting G2/M arrest. Free Radic Biol Med. 2012;52:1486-1493.
135.
PerroneGHideshimaTIkedaHAscorbic acid inhibits antitumor activity of bortezomib in vivo. Leukemia. 2009;23(9):1679-1686.
136.
TisdaleMJ. Mechanisms of cancer cachexia. Physiol Rev. 2009;89:381-410.
137.
FearonKCVon MeyenfeldtMFMosesAGEffect of a protein and energy dense N-3 fatty acid enriched oral supplement on loss of weight and lean tissue in cancer cachexia: a randomized double blind trial. Gut. 2003;52:1479-1486.
138.
FearonKCBarberMDMosesAGDouble-blind placebo-controlled, randomized study of eicosapentaenoic acid diester in patients with cancer cachexia. J Clin Oncol. 2006;24:3401-3407.
139.
JatoiARowlandKLoprinziCLAn eciosapentaenoic acid supplement versus megestrol acetate versus both for patients with cancer-associated wasting: a North Central Cancer Treatment Group and National Cancer Institute of Canada collaborative effort. J Clin Oncol. 2004;22:2469-2476.
140.
van der MeijBSLangiusJASmitEGOral nutritional supplements containing (n-3) polyunsaturated fatty acids affect the nutritional status of patients with stage III non–small cell lung cancer during multimodality treatment. J Nutr. 2010;140:1774-1780.
141.
FinocchiaroCSegreOFaddaMEffect of n-3 fatty acids on patients with advanced lung cancer: a double-blind, placebo-controlled study. Br J Nutr. 2012;108(2):327-333.
142.
MurphyRAMourtzakisMChuQSBaracosVEReimanTMazurakVE. Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer. Cancer. 2011;117:3774-3780.
143.
MurphyRAMourtzakisMChuQSBaracosVEReimanTMazurakVC. Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with non–small cell lung cancer receiving chemotherapy. Cancer. 2011;117(8):1775-1782.
144.
AntounSBaracosVEBirdsellLEscudierBSawyerMB. Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010;21:1594-1598.
BonomiJBattK. Supportive management of mucositis and metabolic derangements in head and neck cancer patients. Cancers. 2015;7:1743-1757.
147.
ZhangZZhuYLingYZhangLWanH. Comparative effects of different enteral feeding methods in head and neck cancer patients receiving radiotherapy or chemoradiotherapy: a network meta-analysis. Onco Targets Ther. 2016;9:2897-2909.
148.
SaylesCHickersonSCBhatRRHallJGareyKWTrivediM. Oral glutamine in preventing treatment-related mucositis in adult patients with cancer: a systematic review. Nutr Clin Pract. 2016;31(2):171-179.
149.
WangWSLinJKLinTCOral glutamine is effective for preventing oxaliplatin-induced neuropathy in colorectal cancer patients. Oncologist. 2007;12:312-319.
150.
DanieleBPerroneFGalloCOral glutamine in the prevention of fluorouracil induced intestinal toxicity: a double blind, placebo controlled, randomised trial. Gut. 2001;48:28-33.
151.
Vidal-CasariegoACalleja-FernándezAde Urbina-GonzálezJJCano-RodríguezICordidoFBallesteros-PomarMD. Efficacy of glutamine in the prevention of acute radiation enteritis: a randomized controlled trial. JPEN J Parenter Enteral Nutr. 2014;38:205-213.
152.
YinSYWeiWCJianFYYangNS. Therapeutic applications of herbal medicines for cancer patients. Evid Based Complement Alternat Med. 2013;2013:302426.
153.
GuoIBaiSPZhaoLWangXH. Astragalus polysaccharide injection integrated with vinorelbin and cisplatin for patients with advanced non–small cell lung cancer: effects on quality of life and survival. Med Oncol. 2012;29(3):1656-1662.
154.
McCullochMSeeCShuXJAstragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006;24:419-430.
155.
WangSFWangQJiaoLJAstragalus-containing Traditional Chinese Medicine, with and without prescription based on syndrome differentiation, combined with chemotherapy for advanced non-small-cell lung cancer: a systemic review and meta-analysis. Curr Oncol. 2016;23(3):e188-e195.
156.
FleischerTChangeTTChiangJHSunMFYenHR. Improved survival with integration of Chinese herbal medicine therapy in patients with acute myeloid leukemia: a nationwide population-based cohort study [published online August 16, 2016]. Integr Cancer Ther.
157.
ChenMMayBHZhouIWSzeDMXueCCZhangAL. Oxaliplatin-based chemotherapy combined with traditional medicines for neutropenia in colorectal cancer: a meta-analysis of the contributions of specific plants. Crit Rev Oncol Hematol. 2016;105:18-34.
158.
Bonnefont-RousselotDCollinF. Melatonin: action as antioxidant and potential applications in human disease and aging. Toxicology. 2010;278:53-67.
159.
LissoniPChilelliMVillaSCerizzaLTanciniG. Five years survival in metastatic non–small cell lung cancer patients treated with chemotherapy alone or chemotherapy and melatonin: a randomized trial. J Pineal Res. 2003;35:12-15.
160.
MillsEWuPSeelyDGuyattG. Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res. 2005;39:360-366.
161.
GuerreroGMReiterRJ. Melatonin-immune system interactions. Curr Topics Med Chem. 2002;2:167-180.
162.
SeelyDWuPFritzHMelatonin as adjuvant cancer care with and without chemotherapy: a systematic review and meta analysis of randomized trials. Integr Cancer Ther. 2012;11:293-303.
163.
LissoniPMeregalliSNosettoLIncreased survival time in brain glioblastomas by a radioneuroendocrine strategy with radiotherapy plus melatonin compared to radiotherapy alone. Oncology. 1996;53(1):43-46.
164.
Del FabbroEDevRHuiDPalmerLBrueraE. Effects of melatonin on appetite and other symptoms in patients with advanced cancer and cachexia: a double-blind placebo-controlled trial. J Clin Oncol. 2013;31:1271-1276.
LadasEKrollDOverliesNA randomized, controlled, double-blind, pilot study of milk thistle for the treatment of hepatotoxicity in childhood acute lymphoblastic leukemia (ALL). Cancer. 2010;116(2):506-513.
168.
ElyasiSHosseiniSMoghadamMRNAledavoodSAKarimiG. Effect of oral silymarin administration on prevention of radiotherapy induced mucositis: a randomized, double-blinded, placebo-controlled clinical trial. Phytother Res. 2016;30:1879-1885.
169.
Becker-SchiebeMMengsUSchaeferMTopical use of a silymarin-based preparation to prevent radiodermatitis: results of a prospective study in breast cancer patients. Strahlenther Onkol. 2011;187(8):485-491.
170.
VidlarAVostalovaJUlrichovaJThe safety and efficacy of a silymarin and selenium combination in men after radical prostatectomy—a six month placebo-controlled double-blind clinical trial. Biomed Pap Med Fac Univ Palace Olomouc Czech Repub. 2010;154(3):239-244.
171.
Cheng-LiangYLiuYYMaYGCurcumin blocks small cell lung cancer cells migration, invasion, angiogenesis, cell cycle and neoplasia: through Janus kinase-STAT3 signalling pathway. PLoS One. 2012;7(5):e37960.
172.
DhillonNAggarwalBBNewmanRAPhase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res. 2008;14:4491-4499.
173.
SharmaRAMcLellandHRHillKAPharmacodynamic and pharmacokinetic study of oral curcuma extract in patients with colorectal cancer. Clin Cancer Res. 2001;7:1894-1900.
174.
MahammediHPlanchatEPougetMThe new combination docetaxel, prednisone and curcumin in patients with castration-resistant prostate cancer: a pilot phase II study. Oncology. 2016;90(2):69-78.
175.
RaoSDinkarCVaishnavLKThe Indian spice turmeric delays and mitigates radiation-induced oral mucositis in patients undergoing treatment for head and neck cancer: an investigational study. Integr Cancer Ther. 2013;13(3):201-210.
SomasundaramSEdmundNAMooreDTDietary curcumin inhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res. 2002;62(13):3868-3875.
178.
NeeratiPDevdeRGangiAK. Evaluation of the effect of curcumin capsules on glyburide therapy I patients with type-2 diabetes mellitus. Phytother Res. 2014;28(12):1796-1800.
179.
AggarwalBBBhardwajAAggarwalRSSeeramNPShishodiaSTakadaY. Role of resveratrol in prevention and therapy of cancer: preclinical and clinical studies. Anticancer Res. 2004;24(5A):2783-2840.
180.
ChakrabortySLevensonASBiswasPK. Structural insights into resveratrol’s antagonist and partial agonist actions on estrogen receptor alpha. BMC Struct Biol. 2013;13:27.
ManusirivithayaSSripramoteMTangitgamolSAntiemetic effect of ginger in gynecologic oncology patients receiving cisplatin. Int J Gynecol Cancer. 2004;14(6):1063-1069.
183.
FahimiFKhodadadKAminiSEvaluating the effect of Zingiber officinalis on nausea and vomiting in patients receiving cisplatin based regimens. Iran J Pharm Res. 2010;10:379-384.
184.
PanahiYSaadatASahebkarAEffect of ginger on acute and delayed chemotherapy-induced nausea and vomiting: a pilot, randomized, open-label clinical trial. Integr Cancer Ther. 2012;11:204-211.
185.
RyanJLHecklerCERoscoeJAGinger (Zingiber officinale) reduces acute chemotherapy-induced nausea: a URCC CCOP study of 576 patients. Support Care Cancer. 2012;20:1479-1489.
186.
ZickSRuffinMLeeJPhase II trial of encapsulated ginger as a treatment for chemotherapy-induced nausea and vomiting. Support Care Cancer. 2009;17:563-572.
MarxWMcCarthyALRiedKCan ginger ameliorate chemotherapy-induced nausea? Protocol of a randomized double blind, placebo-controlled trial. BMC Complement Altern Med. 2014;14:134.
189.
LeungKWWongAST. Pharmacology of ginsenosides: a literature review. Chin Med. 2010;5:20.
190.
BartonDLSooriGSBauerBAPilot study of Panax quinquefolius (American ginseng) to improve cancer-related fatigue: a randomized, double-blind, dose-finding evaluation. NCCTG trial N03CA. Support Care Cancer. 2010;18(2):179-187.
191.
BartonDLLiuHDakhilSRWisconsin Ginseng (Panax quinquefolius) to improve cancer-related fatigue: a randomized, double-blind trial, N07C2. J Natl Cancer Inst. 2013;105(16):1230-1238.
BrownAC. An overview of herb and dietary supplement efficacy, safety and government regulations in the United States with suggested improvements: part 1 of 5 series [published online November 3, 2016]. Food Chem Toxicol.
195.
BrownAC. Liver toxicity related to herbs and dietary supplements: online table of case reports. Part 3 of 6 [published online July 8, 2016]. Food Chem Toxicol.
196.
ZhouSFXueCCYuXQLiCWangG. Clinically important drug interactions potentially involving mechanism-based inhibition of cytochrome P450 3A4 and the role of therapeutic drug monitoring. Ther Drug Monit. 2007;29(6):687-710.
197.
KaegiE. Unconventional therapies for cancer: 1. essiac. The Task Force on Alternative Therapies of the Canadian Breast Cancer Research Initiative. CMAJ. 1998;158:897-902.
MoertelCGFlemingTRRubinJA clinical trial of amygdalin (Laetrile) in the treatment of human cancer. N Engl J Med. 1982;306(4):201-206.
200.
MilazzoSErnstELejeuneSLaetrile treatment for cancer. Cochrane Database Syst Rev. 2011;(11):CD005476.
201.
LindeKJonasWBMelchartDWillichS. The methodological quality of randomized controlled trials of homeopathy, herbal medicines and acupuncture. Int J Epidemiol. 2001;30(3):526-531.
